Does TRASTUZUMAB Cause Second primary malignancy? 101 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 101 reports of Second primary malignancy have been filed in association with TRASTUZUMAB (Trazimera). This represents 0.2% of all adverse event reports for TRASTUZUMAB.
101
Reports of Second primary malignancy with TRASTUZUMAB
0.2%
of all TRASTUZUMAB reports
51
Deaths
15
Hospitalizations
How Dangerous Is Second primary malignancy From TRASTUZUMAB?
Of the 101 reports, 51 (50.5%) resulted in death, 15 (14.9%) required hospitalization, and 8 (7.9%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TRASTUZUMAB. However, 101 reports have been filed with the FAERS database.
What Other Side Effects Does TRASTUZUMAB Cause?
Diarrhoea (4,996)
Off label use (3,802)
Nausea (3,499)
Fatigue (3,417)
Myelosuppression (2,552)
Disease progression (2,449)
Death (2,378)
Vomiting (2,244)
Dyspnoea (2,010)
Pyrexia (1,886)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which TRASTUZUMAB Alternatives Have Lower Second primary malignancy Risk?
TRASTUZUMAB vs TRASTUZUMAB-ANNS
TRASTUZUMAB vs TRASTUZUMAB DERUXTECAN
TRASTUZUMAB vs TRASTUZUMAB-DKST
TRASTUZUMAB vs TRASTUZUMAB-DTTB
TRASTUZUMAB vs TRASTUZUMAB EMTANSINE